lifestyle.ideacrossing.org

Author: AlzeCure Pharma

AlzeCure Pharma Carries Out a Fully Secured Rights Issue of Approximately SEK 30.1 million

April 26, 2026
AlzeCure Pharma to Present at Redeye Alzheimer’s Theme Event on April 9

April 1, 2026
AlzeCure Presents New Preclinical Data with NeuroRestore ACD856 at the Alzheimer’s Conference AD/PD

March 19, 2026
AlzeCure Pharma to Present at Stora Aktiedagarna in Stockholm on March 11

March 4, 2026
AlzeCure Publishes its Year-End Report for January – December 2025

February 26, 2026
Pain Project ACD440 Granted Orphan Drug Status in the EU

February 24, 2026
AlzeCure Abstract on NeuroRestore ACD856 accepted at the Alzheimer’s conference AP/PD 2026

February 3, 2026
AlzeCure Pharma Selected to Present at the Bio-Neuroscience conference in Amsterdam

February 2, 2026